Status:

COMPLETED

Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty

Lead Sponsor:

University of Pisa

Collaborating Sponsors:

Eli Lilly and Company

Conditions:

Myocardial Infarction

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Abciximab has been demonstrated to improve outcome when administered during primary angioplasty in patients with acute myocardial infarction. The Primary Objective of the study is to demonstrate that ...

Detailed Description

Strategies directed at improving myocardial perfusion or viability in the setting of acute myocardial infarction (AMI) are currently suboptimal. The consequences of microvascular damage, as assessed b...

Eligibility Criteria

Inclusion

  • Prolonged, continuous signs and symptoms of ischemia lasting more than 20 min, starting within 6 hours prior to randomization, and ST segment elevation ≥ 2mm or new left bundle branch block
  • Absence of contraindications to Abciximab (for details cf. below section)
  • Written informed consent

Exclusion

  • Low-risk (ST elevation in ≤2 leads) inferior AMI
  • Previous infarction in the same area (assessed by ECG)
  • PCI in the 2 weeks prior to AMI
  • Know hypersensitivity to abciximab
  • Active internal bleeding
  • History of cerebrovascular accident in the previous 2 years or cerebrovascular accident with a significant residual neurological deficit
  • Head or spine surgery or trauma in the previous 2 months
  • Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance
  • Administration of oral anticoagulants within seven days unless prothrombin time is \<1.2 times control
  • Bleeding diathesis or severe uncontrolled arterial hypertension
  • Thrombocytopenia (\<100 000 cells/mL)
  • Recent (within six weeks) major surgery or trauma
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Severe renal or liver failure
  • Allergy to aspirin
  • Contraindication to MRI examination

Key Trial Info

Start Date :

April 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT00354406

Start Date

April 1 2006

End Date

December 1 2008

Last Update

November 16 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cardiothoracic Department, Ospedale Cisanello

Pisa, Italy, 56124